1 / 25

Chapter 31 Antithrombotic therapy

Chapter 31 Antithrombotic therapy. August 8, 2005. Heparin induced thrombocytopenia (HIT). Characterized by formation of antibodies against the heparin-platelet factor 4 complex, type II

peyton
Télécharger la présentation

Chapter 31 Antithrombotic therapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chapter 31 Antithrombotic therapy August 8, 2005

  2. Heparin induced thrombocytopenia (HIT) • Characterized by formation of antibodies against the heparin-platelet factor 4 complex, type II • Type I due to direct effect of heparin on platelet activation, occurs within the first two days and often normalizes with continued heparin administration

  3. HIT incidence • Frequency of 0.3 to 3% in patients exposed to heparin for more than 4 days • One randomized study of heparin vs LMWH for hip surgery prophylaxis HIT incidence was 2.7% vs 0% for those on LMWH • SQ unfractionated heparin had an incidence of 0.8% for HIT with 598 consecutive medical patients • Amount required can be as small as 250u from heparin flushes or heparin coated catheters

  4. HIT pathophysiology • IgG and IgM antibodies provoked not by heparin alone but complex of heparin and platelet factor 4 • Heparin-PF4-antibody complex binds to platelet surface and leads to platelet activation that further releases PF4 causing a positive feedback loop • Activated platelets aggregate and are removed prematurely from circulation leading to thrombocytopenia and frequently thrombosis

  5. HIT clinical presentation • Typically occurs 4 to 10 days after initiation of heparin • Earlier onset seen in patients treated with heparin in preceeding 3 to 4 months • Thrombocytopenia is rarely severe with platelet counts over 20k, median platelet count nadir of 60k • Spontaneous bleeding is unusual • Delayed onset HIT • Can occur after heparin has been withdrawn, avg 9 days later, patients have high titer platelet activating antibodies in one study of 12 patients • 14 patients avg time 14 days (9 to 40 days), 11 patients readmitted and treated with heparin resulting in thrombocytopenia and clinical deterioration and death in 3 patients • Criteria for delayed onset HIT, 1 exposure to heparin with benign hospital course, 2 representation with venous and/or arterial thrombosis, 3 positive serological tests for heparin-induced antibodies

  6. HIT thrombosis • 89% of 9 patients with HIT developed thrombosis (7 venous and 1 arterial) after hip surgery • Retrospective review of 127 with HIT, 78 (61%) patients venous thrombosis and 18 (14%) patients arterial thrombosis, P/E manifested occurred in 25% of these patients, patient with isolated thrombocytopenia had a 30 day risk of thrombosis of 53%

  7. HIT diagnostic testing • Clinical diagnosis • Unexplained thrombocytopenia, thrombosis associated with thrombocytopenia, or normal platelet count that has fallen more than 50% • Serotonin release assay • 14C-serotonin release assay is gold standard • Normal donor platelets labeled with C14-serotonin, washed, then patient serum is added along with low and high concentration heparin • Positive test occurs with release of C14-serotonin with therapeutic concentrations of heparin (0.1u/Ml) • Very expensive • Heparin induced platelet aggregation • Very specific (>90%) but with low sensitivity • Solid phase immunoassay • Not a functional assay • Sensitive >91% but not specific as many antibody positive patients do not develop clinical HIT • Best used in conjunction with one of the other tests

  8. HIT thrombosis • Other clinical manifestations • Venous limb gangrene (distal ischemic necrosis followed by DVT) • Cerebral sinus thrombosis • Upper extremity DVT • 260 cases, upper extremity DVT present in 5.4% of cases, all occurred in patients with central venous catheters and at catheter site • Arterial thrombosis • Stroke • MI • Limb ischemia from peripheral artery occlusion • Organ infarction (mesentery, kidney) • Skin necrosis • Similar to warfarin induced skin necrosis but patients not deficient in protein C/S or antithrombin

  9. HIT prevention • Low incidence of heparin dependent IgG antibodies 2.2% vs. 7.8% with use of LMWH • Warfarin should not be given to HIT patients until thrombocytopenia resolves and therapy should be bridged by argatroban or hirudin, LMWH should not be substituted after HIT

  10. HIT treatment • Immediate cessation of all exposure to heparin • Consider direct thrombin inhibitor lepirudin or argatroban to bridge anticoagulation therapy • Warfarin • Start when patient stably anticoagulated with a thrombin specific inhibitor and platelet count increased to 100k • Warfarin therapy alone may increase risk of venous limb gangrene in patients with DVT • High initial doses >= 10 mg should be avoided to minimize transient hypercoagulable state induced by decline in protein C levels • Anticoagulation should be continued for 2 to 3 months

  11. Direct thrombin inhibitors • Hirudin derivative • Lepirudin, renally excreted and monitored using aPTT, initial bolus of 0.4mg/kg followed by infusion of 0.15mg/kg/hr to keep aPTT 1.5 to 2.5 greater than baseline • Lepirudin approved for treatment of HIT • Lepirudin as safe and effective as heparin for unstable angina, adjunct to thrombolytic therapy, prophylaxis and treatment of VTE • Hirulogs • Bivalirudin (angiomax) monitored by ACT to maintain >350 secs • Only direct thrombin inhibitor approved for acute coronary syndromes • Decrease rate of clinically significant bleeding compared to heparin 3.5% vs. 9.3%.

  12. Small molecule direct thrombin inhibitors • Argatroban • Only one FDA approved • Borderline increased risk of MI and lower rates of major bleeding • Hepatically cleared 2ug/kg/min adjusted to maintian aPTT at 1.5 to 3 times baseline, 0.5ug/kg/min for patients with hepatic dysfunction • Ximelagatran • Oral bioavailability of 18 to 24% • Transformed to melagatran • Compared to dalteparin, combination of ximelagatran and melagatran reduced frequency of VTE in ortho patients from 28.2% to 15.1% • Dosing not influenced by age, gender, or weight and does not require monitoring • Ximelagatran vs. warfarin reduced incidence of VTE and death 20.3% vs. 27.6% with total knee replacement patients and no increased risk of bleeding but elevated transaminases were identified 6.4% vs 1.2% (placebo)

  13. HIT use of heparin later • Brief use of heparin during cardiopulmonary bypass has been successful • But consider if alternative anticoagulants are available • Prove that HIT antibodies are not detectable • Restrict use of heparin to operative procedure itself • Use alternative anticoagulant pre/post op (eg, lepirudin, warfarin)

  14. Factor Xa inhibitors • Fondaparinux (arixtra) • Inhibit thrombin generation • Reduced odds of VTE when compared to enoxaparin in major othropedic cases (6.8% vs. 13.7%) but at the cost of increased major bleeding events (2.7% vs. 1.7%) • Patients with acute symptomatic pulmonary embolism no significant difference in recurrent thromboembolism (3.8% vs. 5%) and major bleeding (1.3% and 1.1%)

  15. Antiplatelet agents • Aspirin • Permanently inactivates cyclooxygenase activity of prostaglandin H synthase-1 and 2 • Short half-life but able to completely inhibit platelet thromboxane A2 production • Equally effective in low doses (50 to 100 mg/day) vs. high doses (900-1500 mg/day) • Ticlopidine and clopidogrel • Selectively inhibit ADP-induced platelet aggregation • Ticlopidine effectively reduces mortality in claudicants by 29.1% • Potential side effects include bone marrow suppresion, aplastic anemia, and thrombocytopenic purpura • Clopidogrel six time more potent than ticlopidine and has a better safety profile, at 50 to 100 mg, requires 4 to 7 days to reach steady state, loading doses of 300 mg may result in more rapid effectiveness • Bleeding risk similar to ASA and ASA is more likely to cause GI bleeding

  16. Antiplatelet agents • Clopidogrel • In patients with PVD, recent stroke, or recent MI reduced risk of stroke, MI or vascular death by 23.8% compared to ASA (3.71% compared to 4.86%) • In patients with acute coronary syndromes with ST segment elevation, combination of ASA and clopidrogrel reduced incidence of CV death, non-fatal MI or stroke from 11.4% to 9.3%, this came at the cost of major bleeding from GI and puncture sites • Compared to placebo combination of ASA and clopidogrel found to increase risk of bleeding (24% vs. 42%) without reduction in thrombotic events in patients with PTFE hemodialysis grafts • Abciximab • GP-IIb/IIIa inhibitor (inhibits fibrinogen binding) reduces rate of death, MI, or urgent revascularization in patients undergoing PCI as well as a reduction in 1 year mortality • When used in conjunction with carefully managed heparin and early removal of arterial sheaths, major bleeding rates are similar to the use of heparin alone • May be associated with thrombocytopenia

  17. Antiplatelet agents • Consensus statement that ASA 325 mg/day be started preoperatively for all prosthetic conduits; grafts to the tibial-peroneal arteries; complex reconstructions requiring composite grafts or endarterectomy; and suboptimal bypasses with limited runoff or requiring a compromised conduit • Combination of warfarin and ASA to maintain an INR of 2 to 3 improved three year primary graft patency and limb salvage rate of 74% and 81% respectively compared with 51% and 31% alone

  18. Reversal of anticoagulants • Unfractionated heparin • Protamine 1 mg per 100 units, risks bradycardia and hypotension • Allergic reactions due to previous exposure to protamine containing insulin, vasectomy and fish allergies • LMWH • Protamine less effective due to shorter heparin chains • Normal dosing acutely reverses 42% of factor Xa activity and 92% of anti-factor IIa actvity • Warfarin • Oral vitamin K reduces INR in 24 hrs • Low dose IV doses effective (0.5 to 2.5mg), higher doses (>10mg) associated with temporary warfarin resistance on reintroduction

  19. Reversal of anticoagulants • Warfarin • INR <5 and no bleeding => lowering or omitting a dose • INR >5 and <9 and no bleeding => withhold 1 to 2 doses +/- 1 to 2.5mg of oral vitamin K • INR >9 3 to 5mg of oral vitamin K • For serious bleeding => FFP and slow IV administration of 10mg vitamin K • In preparation for surgery, most patients require 4 days to reach an INR <1.5 after discontinuation of therapy

  20. Reversal of anticoagulants • For VTE, preoperative heparin for INR <2.0 in those with an event within 1 month • Postoperative heparin for those with an event in preceeding 3 months • For cardiogenic thromboembolism, preoperative anticoagulation for those with an event in the preceeding month • For low risk patients (remote >3 month hx of DVT, or atrial fibrillation without stroke) no heparin is indicated • High risk patients (recent DVT, prosthetic mitral valves, or older mechanical valves) warfarin D/C 4 days prior with full bridging heparin anticoagulation when INR <2

  21. 2004;126;204-233 Chest Hylek Jack Ansell, Jack Hirsh, Leon Poller, Henry Bussey, Alan Jacobson and Elaine Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy The Pharmacology and Management of the Vitamin K Antagonists: The

  22. Reversal of anticoagulants • Newer anticoagulants • No specific antidote for factor Xa inhibitors • Protamine ineffective against direct thrombin inhibitors • Lepirudin and bivalirudin can be partially cleared by hemodialysis

More Related